PMID- 10626784
OWN - NLM
STAT- MEDLINE
DCOM- 20000124
LR  - 20210103
IS  - 0008-5472 (Print)
IS  - 0008-5472 (Linking)
VI  - 59
IP  - 24
DP  - 1999 Dec 15
TI  - Flt3-ligand administration after radiation therapy prolongs survival in a murine 
      model of metastatic lung cancer.
PG  - 6028-32
AB  - An ineffective tumor-specific immune response from inadequate/incompetent antigen 
      presentation could contribute to the failure in tumor control and its 
      dissemination. Dendritic cells (DCs) have been shown to present antigen from 
      apoptotic cells. We hypothesized that Flt3-ligand (Flt3L) therapy, which expands 
      DCs in vivo, in combination with local tumor radiotherapy (RT), should improve 
      antigen presentation from dying, irradiated tumor cells. RT + Flt3L reduced 
      pulmonary metastases in a murine model of Lewis lung carcinoma and significantly 
      improved survival in C57Bl/6 mice with established footpad tumors. Mice treated 
      with Flt3L alone showed delayed tumor growth but eventually succumbed to tumor 
      progression. The combination therapy of RT + Flt3L failed to impact survival in 
      immunodeficient athymic mice, implicating the role of T cells in prolonging 
      survival. These results support an attractive strategy of sequential RT and 
      immunotherapy with Flt3L to enhance tumor antigen presentation, which may produce 
      therapeutic responses against disseminated cancer and improvement in survival.
FAU - Chakravarty, P K
AU  - Chakravarty PK
AD  - Department of Radiation Oncology, Albert Einstein College of Medicine, Montefiore 
      Medical Center, Bronx, New York 10461, USA.
FAU - Alfieri, A
AU  - Alfieri A
FAU - Thomas, E K
AU  - Thomas EK
FAU - Beri, V
AU  - Beri V
FAU - Tanaka, K E
AU  - Tanaka KE
FAU - Vikram, B
AU  - Vikram B
FAU - Guha, C
AU  - Guha C
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Membrane Proteins)
RN  - 0 (flt3 ligand protein)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*therapeutic use
MH  - Combined Modality Therapy
MH  - Disease Models, Animal
MH  - Lung Neoplasms/diagnostic imaging/*drug therapy
MH  - Male
MH  - Membrane Proteins/*therapeutic use
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Nude
MH  - Neoplasm Metastasis/prevention & control
MH  - Neoplasm Transplantation
MH  - Radiography
EDAT- 2000/01/08 00:00
MHDA- 2000/01/08 00:01
CRDT- 2000/01/08 00:00
PHST- 2000/01/08 00:00 [pubmed]
PHST- 2000/01/08 00:01 [medline]
PHST- 2000/01/08 00:00 [entrez]
PST - ppublish
SO  - Cancer Res. 1999 Dec 15;59(24):6028-32.